The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Efficacy of the Royal Marsden Score (RMS) to improve the selection patients (pts) considered for participation to dose-seeking phase I trial.
Veronique Favre
No relevant relationships to disclose
Fatima-Zhora Meniai
No relevant relationships to disclose
Philippe Alexandre Cassier
No relevant relationships to disclose
Carlos Alberto Gomez-Roca
No relevant relationships to disclose
Nicolas Isambert
No relevant relationships to disclose
Stephanie Clisant
No relevant relationships to disclose
Peggy Philippe
No relevant relationships to disclose
Alice Levart
No relevant relationships to disclose
Isabelle Desmoulins
No relevant relationships to disclose
Juliette Bouchet
No relevant relationships to disclose
Jean-Pierre Delord
No relevant relationships to disclose
Nicolas Penel
Research Funding - Bayer; Janssen; Novartis; PharmaMar; Roche